Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
questcor.com

See what CB Insights has to offer

Founded Year

1990

Stage

Acq - P2P | Acquired

Total Raised

$14M

Valuation

$0000 

About Questcor Pharmaceuticals

Questcor Pharmaceuticals is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Our specific areas of focus are in the fields of neurology, nephrology and rheumatology and we are currently supporting research efforts in a variety of conditions having significant unmet medical need.

Questcor Pharmaceuticals Headquarter Location

1300 North Kellogg Drive Suite D

Anaheim, California, 92807,

United States

714-786-4200

Latest Questcor Pharmaceuticals News

Infantile Spasm Treatment Market Rich Product Pipeline and Effective Care Technologies

Sep 14, 2021

Infantile Spasm Treatment Market Rich Product Pipeline and Effective Care Technologies Overview: Infantile spasms, or west syndrome, is a rare type of epilepsy in children. It is considered an epileptic encephalopathy or severe brain disorder. It is a complex and rare disorder that can have very serious consequences. It can lead to death in some babies, and cause intellectual disabilities and developmental problems in others. Many children with infantile spasms develop other kinds of epilepsy. It can be cured, but successful treatment often depends on prompt diagnosis. Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies. Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.coherentmarketinsights.com/insight/request-sample/2453 Drivers: Increasing demand for cost-effective drugs (generic versions) to treat infantile spasm is expected to propel the global infantile spasm treatment market growth over the forecast period. For instance, in May 2018, Amneal Pharmaceuticals announced the launch of vigabatrin for oral solution USP, a generic equivalent for Sabril. Moreover, the company filed Abbreviated New Drug Application (ANDA) to the Food and Drug Administration (FDA) for the tablet form of vigabatrin. Moreover, in July 2018, Aucta Pharmaceuticals begun shipping Vigabatrin 500 mg, following final approval from FDA for its Abbreviated New Drug Application. Furthermore, market players are adopting various strategies, such as mergers and acquisitions, to strengthen their product portfolio, which in turn is expected to drive growth of the global infantile spasm treatment market. For instance, in 2014, Mallinckrodt plc and Questcor Pharmaceuticals, entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately US$ 5.6 billion. Segmentation Analysis: Parenteral If opting for the Global version of Infantile Spasm Treatment Market analysis is provided for major regions as follows: North America (The US, Canada, and Mexico) Europe (the UK, Germany, France, and Rest of Europe) Asia Pacific (China, India, and Rest of Asia Pacific) Latin America (Brazil and Rest of Latin America) Middle East & Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa) Major Players: Major players active in the global infantile spasm treatment market are H. Lundbeck A/S, Catalyst Pharmaceuticals, Mallinckrodt Pharmaceuticals Inc., GW Pharmaceuticals, Retrophin Inc., Insys therapeutics, Valerion Pharma SA, and Anavex Life Sciences Corp. Buy This Complete A Business Report With Flat US $2000 Off @ Section 1: Global Infantile Spasm Treatment Industry Overview Section 2: Global Economic Impact on Infantile Spasm Treatment Industry Section 3: Global Market Competition by Industry Producers Section 4: Global Productions, Revenue (Value), according to Regions Section 5: Global Supplies (Production), Consumption, Export, Import, geographically Section 6: Global Productions, Revenue (Value), Price Trend, Product Type Section 7: Global Market Analysis, on the basis of Application Section 8: Infantile Spasm Treatment Market Pricing Analysis Section 9: Market Chain, Sourcing Strategy, and Downstream Buyers Inquire more about this report @  https://www.coherentmarketinsights.com/insight/talk-to-analyst/2453 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services. To know more about us, please visit our website –  www.coherentmarketinsights.com Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Questcor Pharmaceuticals Patents

Questcor Pharmaceuticals has filed 7 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Adrenal gland disorders
  • Amyotrophic lateral sclerosis
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/19/2016

5/14/2019

Kidney diseases, Nephrology, Autoimmune diseases, Syndromes, Rare diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/19/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/14/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Kidney diseases, Nephrology, Autoimmune diseases, Syndromes, Rare diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.